Key tafenoquine trials
| S. no | Trial/study | Place/year | Total no. of participants | Recurrence free rate of CQ+PQ | Recurrence free rate of CQ+TQ (single dose) |
| 1. | DETECTIVE Part 1 NCT01376167 Phase IIb/III trial25 | Brazil Peru India Thailand 2011–2013 | 329 total | 77% (95% CI 63% to 87%) | 50 mg: 58% (95% CI 43% to 70%) 100 mg: 54% (95% CI 40% to 66%) 300 mg: 89% (95% CI 77% to 95%) 600 mg: 92% (95% CI 80% to 97%) |
| 2. | DETECTIVE Part 2 NCT01376167 Phase III Trial26 | Brazil Peru Colombia Thailand Philippines Ethiopia 2015–2016 | 522 total | 70% (95% CI 60% to 77%) | 62% (95% CI 55% to 69%) |
| 3. | GATHER NCT02216123 Phase III Trial22 | Brazil Colombia Ethiopia Peru Thailand Vietnam 2014–2016 | 251 total | 75% (95% CI 64% to 83%) | 73% (95% CI 65% to 79%) |
CQ, chloroquine; PQ, primaquine; TQ, tafenoquine.